Emergent BioSolutions (EBS) Tops Q2 EPS by 19c

Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of $1.07, $0.19 better than the analyst estimate of $0.88. Revenue for the quarter came in at $220.2 million versus the consensus estimate of $208.57 million.

GUIDANCE:

Emergent BioSolutions sees FY2018 revenue of $715-755 million, versus the consensus of $738.54 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance